Abeona Therapeutics (ABEO) CCO sells 9,620 shares for taxes

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Abeona Therapeutics’ Chief Commercial Officer Madhav Vasanthavada reported small stock sales primarily for tax purposes. On June 8, he sold 4,170 shares of common stock in open-market transactions at a weighted average price of $5.4295 per share. On June 9, he sold another 5,450 shares at a weighted average price of $5.3042 per share. A footnote explains that these sales were made to cover tax obligations tied to the vesting of restricted stock awards, indicating they are compensation-related rather than discretionary portfolio trades. After these transactions, he directly held 303,451 shares of Abeona common stock.

Insider Trade Summary

Net Seller: 9,620 shares ($51,549)

Net Sell 2 txns

Insider Vasanthavada Madhav

Role Chief Commercial Officer

Sold 9,620 shs ($52K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,450	$5.3042	$29K
Sale	Common Stock	4,170	$5.4295	$23K

Holdings After Transaction: Common Stock — 303,451 shares (Direct, null)

Footnotes (1)

The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold June 8: 4,170 shares Price June 8: $5.4295 per share Shares sold June 9: 5,450 shares +3 more

6 metrics

Shares sold June 8 4,170 shares Open-market sale of common stock on June 8

Price June 8 $5.4295 per share Weighted average sale price on June 8

Shares sold June 9 5,450 shares Open-market sale of common stock on June 9

Price June 9 $5.3042 per share Weighted average sale price on June 9

Total shares sold 9,620 shares Combined open-market sales disclosed in this Form 4

Shares held after transactions 303,451 shares Direct ownership after June 9 sale

Key Terms

restricted stock awards, weighted average price, open-market sale

3 terms

restricted stock awards financial

"to cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 08:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vasanthavada Madhav

(Last)

(First)

(Middle)

6555 CARNEGIE AVE.,

4TH FLOOR

(Street)

CLEVELAND

OHIO

44103

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		S⁽¹⁾		4,170	D	$5.4295⁽²⁾	308,901	D
Common Stock	06/09/2026		S⁽¹⁾		5,450	D	$5.3042⁽³⁾	303,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Joseph Vazzano, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for its CCO?

Abeona Therapeutics reported that Chief Commercial Officer Madhav Vasanthavada sold 9,620 shares of common stock. The sales occurred over two days in open-market transactions and were linked to tax obligations from vesting restricted stock awards, leaving him with a sizable remaining direct shareholding.

How many Abeona (ABEO) shares did the CCO sell and on which dates?

The CCO sold a total of 9,620 shares of Abeona common stock. He sold 4,170 shares on June 8 and 5,450 shares on June 9 in separate open-market transactions, as disclosed in the Form 4 filing.

At what prices were the Abeona (ABEO) insider shares sold?

The reported prices are weighted averages for multiple trades. On June 8, shares were sold at a weighted average price of $5.4295, and on June 9 at $5.3042, with detailed price ranges noted as being available upon request from the reporting person.

Why did Abeona’s CCO sell shares according to the Form 4 footnote?

The filing states the sale was to cover tax obligations from vesting restricted stock awards. This indicates the transactions were primarily compensation-related, reflecting required tax payments rather than a discretionary shift in the executive’s investment outlook on Abeona stock.

How many Abeona (ABEO) shares does the CCO hold after these transactions?

After the reported sales, the CCO directly holds 303,451 shares of Abeona common stock. This figure, disclosed in the Form 4, shows that the 9,620 shares sold represent a relatively small portion of his overall direct equity position.

Were the Abeona (ABEO) insider sales tied to restricted stock awards?

Yes. A footnote explains the sales were made to cover tax obligations from vesting restricted stock awards. This means the transactions stem from equity compensation vesting, rather than independent open-market selling unrelated to compensation-driven tax liabilities.